Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2025-03-20 Report Publication Anno…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document explicitly states in the title and body: "BioPorto announces the Annual Report for 2024". It provides key financial highlights for FY 2024, guidance for 2025, and includes an attachment link specifically labeled "2024 Annual Report - BioPorto AS". Although it contains elements of an Earnings Release (financial highlights, CEO commentary, guidance), the primary subject and announcement focus is the availability of the full Annual Report for the fiscal year 2024. Since the document is an announcement *about* the Annual Report and contains significant financial data, it is best classified as the comprehensive Annual Report (10-K equivalent for non-US filers, or the primary annual filing) or, if interpreted strictly as the announcement itself, an RPA. Given the substantial content summarizing the full year's performance and outlook, it strongly aligns with the content expected in an Annual Report context, even if it's presented as a press release summarizing it. However, the definition for 10-K is 'Official yearly report covering company activity and full financial performance.' This text is an announcement *of* that report, not the report itself (which is attached). The presence of the attachment link and the announcement structure suggests it is a Report Publication Announcement (RPA). If the document were the full, detailed 10-K filing, 10-K would be appropriate. Since it is a press release announcing the release of the Annual Report, RPA is the most accurate fit based on the provided definitions, especially Rule 2, which favors RPA for announcements of reports.
2025-03-20 English
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is a formal announcement dated March 19, 2025, titled "BioPorto offentliggør i dag forventninger til 2025 samt aspirationer for 2026 og frem mod 2029" (BioPorto today publishes expectations for 2025 and aspirations for 2026 towards 2029). It explicitly provides forward-looking financial guidance (revenue, EBITDA loss) for 2025, targets for 2026, and long-term revenue aspirations for 2029. This content structure—providing specific financial outlooks for the upcoming year and beyond—is characteristic of an Earnings Release (ER) or a preliminary announcement of results/guidance, rather than a full Annual Report (10-K) or a comprehensive Interim Report (IR). Since it is the initial release of these forward-looking financial expectations, the most appropriate classification is Earnings Release (ER). It is not a transcript (CT), a proxy statement (PSI), or a general regulatory filing (RNS) because it contains specific, material financial guidance. FY 2025
2025-03-19 Danish
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is titled "BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029" and provides specific financial targets (revenue, adjusted EBITDA loss) for 2025 and longer-term aspirations for 2026 and 2029. This content—announcing forward-looking financial expectations and performance metrics for the upcoming year(s)—is characteristic of an Earnings Release (ER) or a preliminary announcement related to financial performance, rather than a full Annual Report (10-K) or a comprehensive Interim Report (IR). Since it is an announcement of guidance and key financial highlights rather than the full, audited financial statements, the most appropriate classification is Earnings Release (ER). The document length (6572 chars) is substantial but the content is focused on guidance, not a full regulatory filing. FY 2025
2025-03-19 English
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is titled 'BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029' and is dated March 19, 2025. It provides specific financial targets (revenue, adjusted EBITDA loss) for the upcoming fiscal year (2025) and longer-term aspirations (2026-2029). This content structure—providing forward-looking financial expectations and performance outlook—is characteristic of an Earnings Release (ER) or a Management Discussion & Analysis (MDA). Since this announcement focuses heavily on providing the initial quantitative guidance and key financial highlights for the coming year, it fits best under the Earnings Release (ER) definition, which covers the 'initial announcement of quarterly/periodical financial results (key highlights only)'. Although it contains forward-looking statements typical of MDA, the primary function here is the release of guidance, which aligns with ER. FY 2025
2025-03-19 English
Earnings Release 2025
Earnings Release Classification · 98% confidence The document is a press release from BioPorto A/S, dated March 19, 2025, titled "BioPorto offentliggør i dag forventninger til 2025 samt aspirationer for 2026 og frem mod 2029" (BioPorto today publishes expectations for 2025 and aspirations for 2026 towards 2029). It provides specific financial guidance for 2025 (revenue, adjusted EBITDA loss) and longer-term targets (aspirations for 2026 and 2029 revenue, expected cash flow break-even). This content structure—providing forward-looking financial guidance and key performance indicators for the upcoming year and beyond—is characteristic of an Earnings Release (ER) or a preliminary announcement preceding a full quarterly/annual report. Since it focuses on announcing expectations and key financial metrics rather than being the comprehensive quarterly report itself (which would be an IR), 'ER' is the most appropriate classification. The document is not a transcript (CT), a full annual report (10-K), or a management discussion/analysis (MDA), but rather the initial release of financial outlook. FY 2025
2025-03-19 Danish
Board/Management Information 2025
Board/Management Information Classification · 100% confidence The document is a formal announcement from BioPorto A/S, dated March 4, 2025, titled 'BioPorto A/S offentliggør Jens Due Olsen som bestyrelseskandidat med henblik på udnævnelse af Jens Due Olsen som formand samt opdateringer om andre kandidater' (BioPorto A/S announces Jens Due Olsen as a board candidate with a view to appointing Jens Due Olsen as chairman and updates on other candidates). This content explicitly details changes and nominations for the Board of Directors (Bestyrelsen). This directly matches the definition for Board/Management Information (MANG). Although it mentions the upcoming general meeting (AGM), the primary focus is the board composition announcement, not the meeting materials or voting results.
2025-03-04 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.